Xenetic Biosciences, Inc. XBIO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Xenetic Biosciences, Inc. (XBIO) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$4M, a net margin of -123.7%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 47% a year, a 5-year average ROIC of -37%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 19% below the current price.
About Xenetic Biosciences
Xenetic Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2016 to $3M in 2025, a decline of about 0.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 103% of revenue on research and development.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $3M | $3M | $3M | $2M | $1M | $436942 | $17066 | $0 | $8M | $3M |
| Net income | -$4M | -$3M | -$4M | -$4M | -$7M | -$6M | -$11M | -$13M | -$7M | -$4M | -$54M |
| Free cash flow | — | — | — | — | — | — | — | — | -$6M | $1M | -$9M |
| EPS (diluted) | $-1.55 | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-5.50 | $-17.00 | $-63.30 | $-96.60 | $-49.19 | $-940.67 |
| Net margin | -123.7% | -90.1% | -158.4% | -162.8% | -383.9% | -486.4% | -2493.1% | -74856.6% | — | -47.4% | -1806.9% |
| ROIC | — | -30.3% | -55.3% | -36.4% | -38.9% | -24.7% | -89.7% | -59.1% | -58.0% | -19.7% | -231.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Xenetic Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 19% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Xenetic Biosciences pay a dividend?
Not currently.
Is Xenetic Biosciences a good stock to buy?
We do not give buy or sell advice. Xenetic Biosciences scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.